Virtus ETF Advisers LLC acquired a new stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) in the second quarter, according to its most recent filing with the SEC. The fund acquired 28,643 shares of the biopharmaceutical company’s stock, valued at approximately $308,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. HighTower Advisors LLC grew its stake in Sangamo Therapeutics by 4.4% in the 2nd quarter. HighTower Advisors LLC now owns 48,655 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 2,050 shares in the last quarter. United Capital Financial Advisers LLC grew its stake in Sangamo Therapeutics by 122.3% in the 2nd quarter. United Capital Financial Advisers LLC now owns 74,044 shares of the biopharmaceutical company’s stock valued at $797,000 after buying an additional 40,730 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Sangamo Therapeutics by 8.1% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 91,682 shares of the biopharmaceutical company’s stock valued at $987,000 after buying an additional 6,867 shares in the last quarter. Pictet Asset Management Ltd. grew its stake in Sangamo Therapeutics by 46.0% in the 2nd quarter. Pictet Asset Management Ltd. now owns 634,941 shares of the biopharmaceutical company’s stock valued at $6,838,000 after buying an additional 200,000 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Sangamo Therapeutics by 3.9% in the 2nd quarter. Northern Trust Corp now owns 1,373,469 shares of the biopharmaceutical company’s stock valued at $14,793,000 after buying an additional 51,137 shares in the last quarter. Institutional investors and hedge funds own 69.02% of the company’s stock.

A number of research analysts recently weighed in on the stock. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research report on Monday, July 8th. ValuEngine upgraded shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright started coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They set a “buy” rating and a $16.00 price target for the company. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Sangamo Therapeutics has an average rating of “Hold” and an average price target of $14.00.

Shares of SGMO traded down $0.26 during mid-day trading on Friday, reaching $10.85. 56,509 shares of the stock traded hands, compared to its average volume of 1,006,479. The firm has a fifty day moving average price of $11.31 and a 200 day moving average price of $10.72. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -15.50 and a beta of 2.90. Sangamo Therapeutics Inc has a 1 year low of $6.26 and a 1 year high of $17.35.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.09. The firm had revenue of $17.55 million during the quarter, compared to analyst estimates of $13.58 million. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. The business’s revenue for the quarter was down 18.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.17) EPS. Equities analysts anticipate that Sangamo Therapeutics Inc will post -1.39 EPS for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Article: Buy Rating

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.